select a format

Single User License
USD 2000 INR 130060
Site License
USD 4000 INR 260120
Corporate User License
USD 6000 INR 390180

Alternatively

Request a quote
Request a Customized research
Request for Sample Report

NEWSLETTER BY CATEGORY




Recent Viewed Reports


Why Ken Reasearch?


Testimonials

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements.... "Senior Associate, Booz Allen Hamilton"

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ... "Mohit Mittal, Consultant, KPMG Advisory Services"

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies.... "Mustafa Masood, Financial Analyst , Coldwell Banker Riyadh"

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"


Cancer Anorexia-Cachexia Syndrome-Pipeline Review, H2 2017

Cancer Anorexia-Cachexia Syndrome-Pipeline Review, H2 2017


  • Products Id :- GMDHC9697IDB
  • |
  • Pages: 93
  • |
  • September 2017
  • |
  • |
  Request for Sample Report

Executive Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Cancer Anorexia-Cachexia Syndrome-Pipeline Review, H2 2017, provides an overview of the Cancer Anorexia-Cachexia Syndrome (Oncology) pipeline landscape.

Anorexia is defined as the loss of the desire to eat. Progressive wasting is common in many types of cancer and is one of the most important factors leading to early death in cancer patients. Advanced cancer undergo a wasting syndrome associated with cancer anorexia/cachexia and asthenia. Cancer anorexia or cachexia often is associated with weakness, fatigue, and a poor quality of life. This symptom of anorexia not only affects the patient but also frequently has an impact on family members, as the patient is no longer able to participate fully in eating as a social activity.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Cancer Anorexia-Cachexia Syndrome-Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Cancer Anorexia-Cachexia Syndrome (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Cancer Anorexia-Cachexia Syndrome (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Cancer Anorexia-Cachexia Syndrome and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 4, 1, 1, 9 and 3 respectively. Similarly, the Universities portfolio in Phase I and Preclinical stages comprises 1 and 3 molecules, respectively.

Cancer Anorexia-Cachexia Syndrome (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The pipeline guide provides a snapshot of the global therapeutic landscape of Cancer Anorexia-Cachexia Syndrome (Oncology).

The pipeline guide reviews pipeline therapeutics for Cancer Anorexia-Cachexia Syndrome (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Cancer Anorexia-Cachexia Syndrome (Oncology) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Cancer Anorexia-Cachexia Syndrome (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Cancer Anorexia-Cachexia Syndrome (Oncology)

Reasons to buy

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Cancer Anorexia-Cachexia Syndrome (Oncology).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Cancer Anorexia-Cachexia Syndrome (Oncology) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications
ankur [@] kenresearch.com
+91-9015378249
www.kenresearch.com

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Cancer Anorexia-Cachexia Syndrome-Overview

Cancer Anorexia-Cachexia Syndrome-Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Cancer Anorexia-Cachexia Syndrome-Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Cancer Anorexia-Cachexia Syndrome-Companies Involved in Therapeutics Development

Abreos Biosciences Inc

Acacia Pharma Ltd

Aeterna Zentaris Inc

Incyte Corp

Lakewood-Amedex Inc

Novartis AG

Paradigm Biopharmaceuticals Ltd

RaQualia Pharma Inc

Viking Therapeutics Inc

Zeria Pharmaceutical Co Ltd

Cancer Anorexia-Cachexia Syndrome-Drug Profiles

(formoterol fumarate + megestrol acetate)-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

anamorelin hydrochloride-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Antibody to Inhibit Parathyroid Hormone Related Protein for Cancer Cachexia-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AV-380-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AVGN-7-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

C-1889-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DLN-101-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ENERGIF-706-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

EXT-400-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Foxo1-nRNA-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Fusion Protein to Inhibit Activin A for Osteoporosis and Cancer Cachexia-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HM-03-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IP-1510-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

macimorelin acetate-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NEO-1940-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Recombinant Peptide to Inhibit CIDEA for Cancer Cachexia-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RQ-00433412-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ruxolitinib phosphate-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit ATGL for Cancer Cachexia and Type 2 Diabetes-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Synthetic Peptides for Cancer Cachexia-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TCMCB-07-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VK-5211-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Z-505-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cancer Anorexia-Cachexia Syndrome-Dormant Projects

Cancer Anorexia-Cachexia Syndrome-Discontinued Products

Cancer Anorexia-Cachexia Syndrome-Product Development Milestones

Featured News & Press Releases

May 18, 2017: Helsinn Announces Refusal of the marketing authorisation for Adlumiz (anamorelin hydrochloride)

Feb 13, 2017: Aeterna Zentaris Announces Plans to Pursue FDA Registration of Macrilen

Jun 01, 2016: Helsinn Group to Present at ASCO Pooled Follow up Efficacy Data Analysis From two Phase III Studies for Anamorelin in Cachectic Patients With Non-small Cell Lung Cancer

Feb 23, 2016: Helsinn Announces Publication of Anamorelin ROMANA 1 and ROMANA 2 Phase III Studies in The Lancet Oncology

Nov 30, 2015: Helsinn Announces European Medicines Agency Acceptance of Marketing Authorization Application for Anamorelin HCL

Oct 30, 2014: New Data on Fatigue from ROMANA 1, a Pivotal Phase III Study of Anamorelin in Advanced NSCLC Patients with Cachexia Presented at 2014 Chicago Multidisciplinary Symposium in Thoracic Oncology

Sep 26, 2014: AVEO Oncology Announces Presentation of AV-380 Preclinical Data at 2nd Cancer Cachexia Conference

Aug 28, 2012: Aeterna Zentaris Recruits First Patient For Phase IIA Trial In Cancer Cachexia With AEZS-130

Mar 08, 2012: Michael E. DeBakey Veterans Affairs Medical Center Initiates Phase IIa Trial In Cancer Cachexia With Aeterna Zentaris's Ghrelin Agonist, AEZS-130

Dec 07, 2011: Helsinn Initiates Extension Study In Late-Stage Anamorelin Clinical Program For Non-Small Cell Lung Cancer-Associated Anorexia/Cachexia

Dec 06, 2011: Acacia Pharma Announces Positive Results From Phase IIa Cancer Cachexia Study

Nov 28, 2011: FDA Grants IND To Investigator At Baylor College Of Medicine For Phase IIa Trial With AEZS-130 In Cancer Cachexia

Aug 24, 2011: Helsinn Therapeutics Initiates Phase III Clinical Program To Evaluate Anamorelin In Non-Small Cell Lung Cancer-Associated Anorexia/Cachexia

Apr 26, 2007: Sapphire Therapeutics, Inc. to Present Results From Anamorelin Phase II Cachexia/Anorexia Studies at American Society of Clinical Oncology and Endocrine Society Annual Meetings in June

Dec 15, 2005: Sapphire Therapeutics, Inc.'s Oral Ghrelin Mimetic Shows Potential for Treating Cancer Anorexia/Cachexia

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Figures

Number of Products under Development for Cancer Anorexia-Cachexia Syndrome, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Number of Products by Top 10 Targets, H2 2017

Number of Products by Stage and Top 10 Targets, H2 2017

Number of Products by Top 10 Mechanism of Actions, H2 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017

Number of Products by Routes of Administration, H2 2017

Number of Products by Stage and Routes of Administration, H2 2017

Number of Products by Molecule Types, H2 2017

Number of Products by Stage and Molecule Types, H2 2017

List of Tables

Number of Products under Development for Cancer Anorexia-Cachexia Syndrome, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Products under Development by Companies, H2 2017

Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Products under Development by Universities/Institutes, H2 2017

Number of Products by Stage and Target, H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

Cancer Anorexia-Cachexia Syndrome-Pipeline by Abreos Biosciences Inc, H2 2017

Cancer Anorexia-Cachexia Syndrome-Pipeline by Acacia Pharma Ltd, H2 2017

Cancer Anorexia-Cachexia Syndrome-Pipeline by Aeterna Zentaris Inc, H2 2017

Cancer Anorexia-Cachexia Syndrome-Pipeline by Incyte Corp, H2 2017

Cancer Anorexia-Cachexia Syndrome-Pipeline by Lakewood-Amedex Inc, H2 2017

Cancer Anorexia-Cachexia Syndrome-Pipeline by Novartis AG, H2 2017

Cancer Anorexia-Cachexia Syndrome-Pipeline by Paradigm Biopharmaceuticals Ltd, H2 2017

Cancer Anorexia-Cachexia Syndrome-Pipeline by RaQualia Pharma Inc, H2 2017

Cancer Anorexia-Cachexia Syndrome-Pipeline by Viking Therapeutics Inc, H2 2017

Cancer Anorexia-Cachexia Syndrome-Pipeline by Zeria Pharmaceutical Co Ltd, H2 2017

Cancer Anorexia-Cachexia Syndrome-Dormant Projects, H2 2017

Cancer Anorexia-Cachexia Syndrome-Dormant Projects, H2 2017 (Contd..1), H2 2017

Cancer Anorexia-Cachexia Syndrome-Discontinued Products, H2 2017

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Abreos Biosciences Inc

Acacia Pharma Ltd

Aeterna Zentaris Inc

Incyte Corp

Lakewood-Amedex Inc

Novartis AG

Paradigm Biopharmaceuticals Ltd

RaQualia Pharma Inc

Viking Therapeutics Inc

Zeria Pharmaceutical Co Ltd

Cancer Anorexia-Cachexia Syndrome Therapeutic Products under Development, Key Players in Cancer Anorexia-Cachexia Syndrome Therapeutics, Cancer Anorexia-Cachexia Syndrome Pipeline Overview, Cancer Anorexia-Cachexia Syndrome Pipeline, Cancer Anorexia-Cachexia Syndrome Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

query [@] kenresearch.com